



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Rd,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Wholesale Investor's Sydney Capital Showcase and Australia Biotech Invest, Melbourne

Melbourne, 5 December 2014:

BioDiem's CEO, Julie Phillips presented at the Wholesale Investor Sydney Capital Showcase held on Thursday 20 November 2014 in Sydney and the Australia Biotech Invest event held in Melbourne on 3rd and 4th December.

The BioDiem presentation focused on BioDiem's BDM-I and the opportunity presented by the antimicrobial for collaboration and investment.

ENDS

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. BioDiem's business model is to generate income from partnerships including with other vaccine development companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. For additional information, please visit www.biodiem.com

Further information

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9692 7240
Email jphillips@biodiem.com
Twitter @biodiem



Therapies for major infectious diseases and related cancers

Australia Biotech Invest
3 – 4 December 2014
Crown Conference Centre, Melbourne

Julie Phillips, CEO
jphillips@biodiem.com



Safe Harbour Statement

This presentation is provided to you for information purposes only and should not be construed as an offer, and shall not form part of an offer, or solicitation to buy or sell any securities or derivatives. It should not be considered as an invitation to subscribe for or purchase any securities in BioDiem Limited. or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in BioDiem Limited will be entered into on the basis of this presentation.

To the maximum extent permitted by applicable laws, BioDiem Limited and its affiliates make no representation and can give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility for the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

The contents of this presentation are confidential. The presentation is being provided to you on the condition that you do not reproduce or communicate it to, or disclose it to, or discuss it with, any other person without the prior written permission of BioDiem Limited.

Invasive Fungal Infection after Natural Disasters

Kaitlin Benedict and Benjamin J. Park

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 20, No. 3, March 2014

OXFORD JOURNALS

Clinical Infectious Diseases

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

Dr. Arjun Srinivasan: We've Reached "The End of Antibiotics, Period"

FRONTLINE

October 22, 2013, 9:29 pm ET

THE VERGE

Gonorrhea is about to become impossible to treat

Antibiotic resistance means the STD might soon spread more aggressively



Australia Network News

Calls for action on 'dire' drug-resistant TB threat in Asia and the Pacific

By Jemima Garrett

Posted Mon 14 Apr 2014, 7:05pm AEST

Bulletin of the World Health Organization

Race against time to develop new antibiotics

CBCnews | Health

Superbug threat as grave as climate change, say scientists

'The international response has been feeble'

Thomson Reuters Posted: May 23, 2014 10:53 AM ET | Last Updated: May 23, 2014 10:53 AM ET

Challenges



Increasing resistance

To antibiotics – major concern healthcare systems worldwide



Hard to treat

Fungal infections, affecting vulnerable patients



Increase in prevalence



Due to climate change and vector movements.



Product pipelines diminish

Large Pharma focus on innovation, as product pipelines diminish

BDM-I: Antimicrobial



Novel mechanism of action: Inhibits new target

Protein Tyrosine Phosphatases (PTPs)

- Involved in cell signalling
- Mimics tyrosine

Heterogeneity of PTP function explains

- Selectivity within species
- Difference in function in mammalian cells

Invasive and superficial fungal infections

Some species of

- *Candida*
- *Cryptococcus*
- *Scedosporium*
- *Pneumocystis*

Drug-resistant tuberculosis & gonorrhoea

- *Mycobacterium tuberculosis*
- *Neisseria gonorrhoea*

Some protozoal infections

- *Trichomonas vaginalis*; *Plasmodium falciparum*

and others...



In vitro activity

Group	(µg/ml)	Group	(µg/ml)
Fungi	MIC90 <i>C. glabrata</i> * 1	G-ve bacteria	MIC <i>Neisseria gonorrhoeae</i> 2
	MIC90 <i>C. glabrata</i> ** 2		MIC <i>Campylobacter jejuni</i> 0.5 -2
	MIC90 <i>Coccidioides spp.</i> 0.25*		Other bacteria - potential biological weapons
	MIC90 <i>Coccidioides spp.</i> 0.25**		
	IC50 <i>P. carinii</i> <0.1***	Parasite	<i>Schistosomiasis japonicum</i>
	IC50 <i>P. murina</i> 0.174***		LC50 Adults (5 days)
			LC50 Schistosomulae (24 hrs)
	MIC <i>Scedosporium prolificans</i> (three strains) 1-2		<i>Schistosomiasis masoni</i>
			LC50 Adults (5 days)
			LC50 Schistosomulae (8hrs)

*50% Inhibition Endpoint

**100% Inhibition Endpoint


*** (based on %reduction ATP at Day3)



Poised for proof-of-concept

Product	Disease Targets	Current Partners	Development Status
BDM-I	Tuberculosis & bioterrorism	US govt backed research institutions	Successful screening result: preparation for <i>in vivo</i> testing
	Pneumocystis	US govt backed research institutions	Successful screening result: preparation for <i>in vivo</i> testing
	Scedosporium	Australian site	Successful screening result: seeking disease models

Next Steps:



Complete formulation studies




BDM-I testing in animal models




Clinical trial in orphan disease

Market Size Potential



BioDiem

Potential Product Range





“Generating Antibiotic Incentives Now” legislation

GAIN: How a New Law is Stimulating the Development of Antibiotics

May 28, 2014 | Project: [Antibiotics and Innovation Project](#)

On July 9, 2012, the Generating Antibiotic Incentives Now, or GAIN, provisions were signed into law by President Barack Obama as part of the [Food and Drug Administration Safety and Innovation Act](#). This bipartisan legislation extends by five years the exclusivity period during which certain antibiotics—those that treat serious or life-threatening infections—can be sold without generic competition. This additional period of exclusivity increases the potential for profits from new antibiotics by giving innovative companies more time to recoup their investment costs.

**“GAIN seeks to increase antibiotics’
commercial value....”**

🔍 Global problem in infectious disease

🏆 BDM-I has

- Activity vs important pathogens
- Novel mechanism of action; granted patents
- Collaborations in place with world class facilities



👉 Commercial opportunity for product/pipeline development

- Life threatening and other infections
- Attractive incentives e.g. GAIN legislation

👉 **Opportunity for investment & collaboration for development**

- for niche high value diseases and
- expanded product range



Therapies for major infectious diseases and related cancers

Australia Biotech Invest
3 – 4 December 2014
Crown Conference Centre, Melbourne

Julie Phillips, CEO
jphillips@biodiem.com